Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Petmed Express ( (PETS) ) is now available.
On October 19, 2025, PetMed Express appointed James LaCamp as a director and Audit Committee Chair, effective immediately. LaCamp, with nearly two decades of experience in finance and accounting, is expected to enhance the company’s financial governance and oversight. Additionally, on October 20, 2025, the company entered into an Interim Executive Employment Agreement with Leslie C.G. Campbell, who will serve as Interim CEO and President for a year, highlighting the company’s strategic focus on board composition and leadership to drive growth and shareholder value.
The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
Spark’s Take on PETS Stock
According to Spark, TipRanks’ AI Analyst, PETS is a Neutral.
Petmed Express shows a mixed financial performance with strong balance sheet stability but weak profitability and inconsistent cash flow. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics suggest the stock may be overvalued. The earnings call highlights progress in profitability and strategic investments, but challenges remain in sales and competitive pressures. Overall, the stock score reflects these combined factors, indicating moderate potential with significant risks.
To see Spark’s full report on PETS stock, click here.
More about Petmed Express
PetMed Express, Inc., founded in 1996, is a pioneer in the direct-to-consumer pet healthcare sector. It operates as a national online pharmacy licensed across all 50 states, offering a comprehensive range of pet health solutions, including pharmaceuticals, compounded medications, and OTC supplements through its PETS family of brands and PetCareRx subsidiary.
Average Trading Volume: 122,872
Technical Sentiment Signal: Sell
Current Market Cap: $52.75M
See more data about PETS stock on TipRanks’ Stock Analysis page.